(EN) A method (300) for identifying a binding site of a Valsartan drug, the method comprising: developing pharmacophore models to extract features from the Valsartan drug; validating the developed pharmacophore models by comparing with pre-defined models of existing coronavirus drugs; performing a ligand-based virtual screening (first virtual screening) of a database of drugs with the validated pharmacophore models; performing a structure-based virtual screening (second virtual screening) of the validated pharmacophore models by structural docking of a target protein into the validated pharmacophore models; assigning a score to each pharmacophore model of the Valsartan drug in order to identify the validated pharmacophore models with a high binding affinity and efficiency; and comparing the score obtained from the ligand-based virtual screening (first virtual screening) and the structure-based virtual screening (second virtual screening) for classifying the scored pharmacophore models based on the target protein binding affinity and efficiency for the coronaviridae family of virus.
